Curated News
By: NewsRamp Editorial Staff
August 29, 2024
Syntekabio Introduces 'Develop Now, Pay Later' with AI-Powered STB LaunchPad Program
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Syntekabio's 'Develop Now, Pay Later' offer minimizes risk, saves time and costs, and increases success rate for drug development companies.
- Clients can submit target protein for analysis via the STB LaunchPad program with no upfront costs, paying only after validated results are obtained.
- Syntekabio's mission is to deliver safer and more effective therapies to patients, supporting groundbreaking drug development work and reducing risk for clients.
- Syntekabio's AI accesses over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets, revolutionizing the drug discovery and development process.
Impact - Why it Matters
This news matters as it introduces a groundbreaking offer that could revolutionize the drug development industry. The 'Develop Now, Pay Later' model could significantly reduce the financial risk for pharmaceutical and biotechnology companies, ultimately leading to the development of safer and more effective therapies for patients.
Summary
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, has introduced a new 'Develop Now, Pay Later' offer. This initiative is designed to minimize risk, save time and costs, and increase the success rate of companies developing novel therapies. The model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Syntekabio Introduces 'Develop Now, Pay Later' with AI-Powered STB LaunchPad Program
